cost-effectiveness of the “polypill” for secondary prevention of cvd · 2018. 5. 29. ·...
TRANSCRIPT
![Page 1: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/1.jpg)
Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD
John Lin, MD
The Fifth Annual Global Health Economics Colloquium:
The Economics ofVulnerable Populations,
at Home and Abroad
![Page 2: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/2.jpg)
Background: CVD and Global Health
§Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide
§Low- and middle-income countries (LMIC) face more than 75% of the global burden
§WHO Global Action Plan for Non-Communicable Disease• Reduce premature mortality by 25% by 2025• Increase NCD medication prescription to cover 50% of
eligible population
Cost-Effectiveness of the Polypill in LMIC2
![Page 3: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/3.jpg)
Cost-Effectiveness of the Polypill in LMIC3
Prescription Rates Low in LMIC
Yusuf Lancet 2011, PURE Study
![Page 4: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/4.jpg)
Polypill/Fixed Dose Combination (FDC)
§Combine multiple CVD medicines into one pill§Advantages
• Improves adherence (as in HIV, TB)• Easier to prescribe
§Disadvantages• Difficult to titrate
§Argument for usage in LMIC
Cost-Effectiveness of the Polypill in LMIC4
![Page 5: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/5.jpg)
Polypill/FDC: Policy Implications
§2012: WHO rejected polypill application for its Model List of Essential Medicines• No evidence on efficacy• No evidence on safety• No data on cost-effectiveness
Cost-Effectiveness of the Polypill in LMIC5
![Page 6: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/6.jpg)
Polypill/FDC: The Evidence
§Two RCTs for Secondary Prevention• FOCUS: Argentina, Brazil, Paraguay, Italy, Spain• UMPIRE: India, UK, Netherlands
§ Improved adherence§Demonstrated safety§ Improved BP, LDL-C
Cost-Effectiveness of the Polypill in LMIC6
UMPIRE JAMA 2013
![Page 7: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/7.jpg)
Question: Is the polypill cost-effective relative to usual care for secondary prevention of CVD in LMICs?
Presentation Title and/or Sub Brand Name Here7
![Page 8: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/8.jpg)
Study: Cost-effectiveness of polypill
§Polypill may:• Reduce costs associated with acute events• Increase costs from prescription, prolonged survival
Study Aim: To evaluate the cost-effectiveness of the polypill in China, India, Mexico, Nigeria, and South Africa
Cost-Effectiveness of the Polypill in LMIC8
![Page 9: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/9.jpg)
Analyses
1. What is the cost-effectiveness of polypill prescribed at current rates compared with current prescription?
2. What should we expect if we achieve WHO goals for secondary prevention of CVD?
• Individual medicines prescribed to 50% of eligible• Polypill prescribed to 50% of eligible
Presentation Title and/or Sub Brand Name Here9
![Page 10: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/10.jpg)
Methods§Microsimulation: adults aged 30-80 years in each country with prior ischemic heart disease or stroke.
§Perspective: Health system§Analytic Horizon: Lifetime§Future costs and life years discounted at 3% per year
§Probabilistic Sensitivity Analysis: Vary all input parameters among pre-defined distributions 1000x
Cost-Effectiveness of the Polypill in LMIC10
![Page 11: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/11.jpg)
Methods
§Major cardiovascular events: MI, stroke, CVD death§Disability-adjusted life years averted§Direct medical costs in International Dollars§Cost-effective defined as 1x GDP/capita
Outcomes
Presentation Title and/or Sub Brand Name Here11
![Page 12: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/12.jpg)
Assumptions About Polypill§ Increased adherence compared to individual components§As efficacious as its individual components§Doses can be titrated§Cost is 100% of the sum of its individual components
Cost-Effectiveness of the Polypill in LMIC12
![Page 13: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/13.jpg)
Sensitivity Analyses For The Polypill§ Increased adherence compared to individual components§80% efficacy compared to its individual components§Doses can be titrated§Cost is 200% of the sum of its individual components
Cost-Effectiveness of the Polypill in LMIC13
![Page 14: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/14.jpg)
Cost-Effectiveness of the Polypill in LMIC14
![Page 15: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/15.jpg)
Cost-Effectiveness of the Polypill in LMIC15
![Page 16: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/16.jpg)
Cost-Effectiveness of the Polypill in LMIC16
![Page 17: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/17.jpg)
Cost-Effectiveness of the Polypill in LMIC17
![Page 18: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/18.jpg)
Limitations
§Current modeling does not reflect programmatic costs of scaling up prescription rates
§Cost-effectiveness is distinct from affordability
Cost-Effectiveness of the Polypill in LMIC18
![Page 19: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/19.jpg)
Conclusions
§Cost-effectiveness of the polypill may be better in countries with more developed health systems
§ Impact of increasing prescription may be greater in countries with less health infrastructure
Presentation Title and/or Sub Brand Name Here19
![Page 20: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/20.jpg)
Acknowledgments
§Dhruv Kazi, MD, MSc, MS
§Andrew Moran, MD
§Andrea Tobias, MSc
§Bode Falase, FRCS CTh
§Charuta Mandke, MS, DNB
§VA HSR&D Fellowship
§UCSF CTSI
§UCSF Global Health Pathway
Cost-Effectiveness of the Polypill in LMIC20
![Page 21: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/21.jpg)
Supplemental Slides
Presentation Title and/or Sub Brand Name Here21
![Page 22: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/22.jpg)
Adherence§Usual Care
• Starts at 100% prescription, then declines according to the literature (steady state year 3)
§Polypill
• Starts at 100% of prescription, declines exponentially
§ !"#ℎ%&%'(% = " + (1−") ∗ %−1.3 ∗ *
Cost-Effectiveness of the Polypill in LMIC22
![Page 23: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/23.jpg)
Medication Prescription§PURE Study
• Marginal distribution of medication usage by drug class
• Proportion of individuals taking 1, 2, or 3+ medications
§Calibration to determine correlation structure
• Preserve marginal distribution and proportion taking n number of medications
• Goodness of fit defined by root mean squared distance
• Optimization function: Limited memory BFGS-B
§Problem not identified – multiple solution sets do not change results
Cost-Effectiveness of the Polypill in LMIC23
![Page 24: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/24.jpg)
Cost-Effectiveness of the Polypill in LMIC24
![Page 25: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/25.jpg)
Data Sources§ Demographics and Epidemiology:
• UN population division
• GBD 2015
§ IHD and CVA transition probabilities:
• Observational studies
• Registries: RENAISCA II, BRIG, ACCESS, CREATE
§ Effectiveness of interventions
• Meta-analyses of CVD medication RCTs
§ Adverse effects of interventions
• Meta-analyses of CVD medication RCTs
• UMPIRE, FOCUS
Cost-Effectiveness of the Polypill in LMIC25
§ Adherence to medications:
• Current prescription levels: PURE
• Patient adherence over time: meta-analyses of observational data
• Improvement in adherence with polypill: UMPIRE, FOCUS
§ DALYs
• Global Burden of Disease 2015
§ Costs
• WHO CHOICE
• MSH International Drug Price Indicator Guide
• Personal Correspondence
![Page 26: Cost-Effectiveness of the “Polypill” for Secondary Prevention of CVD · 2018. 5. 29. · Polypill/FDC: The Evidence §Two RCTs for Secondary Prevention •FOCUS: Argentina, Brazil,](https://reader036.vdocument.in/reader036/viewer/2022081523/5fe9274d4a24525a2119f0b7/html5/thumbnails/26.jpg)
Cost-Effectiveness of the Polypill in LMIC26
Model Validation